CP-195543

• UNSPSC Description:

  CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration[1].

• Target Antigen:

  Leukotriene Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cp-195543.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O)C1=CC=C(C(F)(F)F)C=C1C2=CC=C3[C@H](O)[C@@H](CC4=CC=CC=C4)COC3=C2

• Molecular Weight:

  428.40

• References & Citations:

  [1]Showell HJ, et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J Pharmacol Exp Ther. 1998 Jun;285(3):946-54.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  204981-48-6